Table 1 Description of participants included in the epigenetic analyses of insulin resistance (IR) and/or neurological traits
A. Framingham Heart Study (N = 3,167) | |
|---|---|
Age at IR measurement | |
Median [25–75pc] Mean (SD) | 60 [51–68] 60 (13) |
Sex, N Females (%) | 1757 (55) |
BMI, median [25–75pc] Mean (SD) | 27.2 [24.2–30.6] 27.8 (5.2) |
Self-Reported Race, N White, N Black (%) | 3167 (100), 0 (0) |
HOMA-IR (ln), median [25–75pc] Mean (SD) | 0.8 [0.4–1.3] 0.8 (0.6) |
Cohort/Substudy, N (%) | |
GEN3 Offspring/JHU Offspring/UMN | 967 (30.5) 367 (11.6) 1833 (57.9) |
All-cause dementia, N cases (%) | 141 (5) |
Alzheimer’s disease dementia, N cases (%) | 112 (4) |
HV, mean (SD) | 0.005 (0.0005) |
TBV, mean (SD) | 0.78 (0.02) |
LVV, mean (SD) | 0.02 (0.009) |
B. Religious Orders Study (ROS) and Memory and Aging Project (MAP), N = 707 | |
|---|---|
Age at death | |
Median [25–75pc] Mean (SD) | 88 [84–90] 86 (5) |
Sex, N Females (%) | 447 (63) |
Self-reported Race, N White, N Black (%) | 691 (97.7), 13 (1.8) |
Cohort/Substudy, N (%) ROS MAP | 387 (54.7) 319 (45.1) |
Clinical diagnosis of cognitive status at death, N (%) | |
NCI: no cognitive impairment (CI) MCI: mild cognitive impairment, no other condition contributing to CI MCI + : mild cognitive impairment and another condition contributing to CI AD: Alzheimer's dementia, no other condition contributing to CI AD + : Alzheimer's dementia and other condition contributing to CI Other dementia: other primary cause of dementia, no clinical evidence of Alzheimer's dementia | 218 (30.8) 159 (22.5) 12 (1.7) 255 (36.1) 44 (6.2) 18 (2.5) |
BRAAK stage: semiquantitative measure of severity of neurofibrillary tangle pathology, N (%) | |
0 1: stage I 2: stage II 3: stage III 4: stage IV 5: stage V 6: stage VI | 9 (1.3) 57 (8.1) 74 (10.5) 209 (29.6) 199 (28.1) 152 (21.5) 6 (0.8) |
CERAD score: semiquantitative measure of neuritic plaques, N (%) | |
1: definite 2: probable 3: possible 4: no AD | 212 (30.0) 238 (33.7) 72 (10.2) 184 (26.0) |